Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Review Modernization Fully Funded

Generics Modernization Effort At US FDA Receives Full Funding Over Two Years

Executive Summary

After receiving $25.1m in FY 2019, Congress gave another $1.9m in FY 2020, which appropriators said combined reaches the $27m requested for the FY 2020 budget.

You may also be interested in...



Opioid Blister Packs Need Study Before Mandate, Groups Urge

AAM, Upsher-Smith, APhA, and Cigna tell US FDA that packaging requirement will increase manufacturing and drug costs, create reimbursement hurdles and reduce access to medicines. Daiichi-Sankyo supports agency's proposal.

Generic Labeling Problems Targeted In US FDA Budget Request

Agency seeks legislative authority to update outdated generic drug labels when the reference product has been withdrawn.

Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase

The agency requested a funding increase in part to implement 2018 legislation intended to combat the opioid crisis, but also to support many initiatives in last year's budget request.

Related Content

Topics

UsernamePublicRestriction

Register

GB149478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel